• Coronavirus

Dr. Quay speaks with Fox News about origin of COVID-19

As we enter the new year, ongoing efforts to understand and combat COVID-19 persist, with researchers uncovering new insights into the virus’s origins.

Dr. Quay discusses recent findings regarding the initial spread of the virus, highlighting a genetic cluster identified in patients from a military hospital in Wuhan, China, suggesting transmission within a confined group.

By tracing the movement of patients to nearby subway stations and ultimately to the airport, Dr. Quay suggests Line Two of Wuhan’s subway system as a crucial transmission route. This information not only sheds light on the virus’s early spread but also aids in predicting its future mutations, guiding the development of effective therapeutics.

As debates persist regarding whether the virus originated in a seafood market or a laboratory, ongoing research aims to provide clarity in the coming months.

Read the full article on Fox News 26 Houston.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

October 31, 2024

This video describes the clinical data from the Atossa Therapeutics press release of October 31, 2024 entitled, Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Dr. Quay featured in CBS7 on New 2024 COVID Vaccine

September 4, 2024

This summer saw a rise in COVID-19 infections across the U.S., driven by a new variant. To address this, updated vaccines from Moderna and Pfizer have been approved by the FDA and will be available this fall. The CDC notes the virus has been evolving, making regular vaccinations important, especially for those with underlying health conditions.

Lanzamiento de la Nueva Vacuna contra el COVID-19: Lo Que Necesitas Saber para el Otoño de 2024

August 31, 2024

Los casos de COVID-19 están aumentando ligeramente en EE. UU., y se introducirá una nueva vacuna este otoño. Telemundo20 en Texas conversa con el Dr. Quay para discutir los datos más recientes sobre esta vacuna y las precauciones que las personas deben considerar para los próximos meses. A pesar de la presencia continua del virus, actualmente es menos infeccioso y se asemeja a un resfriado común en términos de transmisión.

Join Dr. Quay’s ElevatorMedicine™ and get FREE, QUICK TIPS for better living, health, and wellness that take less time than riding an elevator!